Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma

The prognosis of patients with advanced hepatocellular carcinoma (HCC) is very poor. The AKT pathway is activated in almost half of HCC cases and in addition, long term exposure to conventional drug treatment of HCC, sorafenib, often results in over-activation of AKT, leading to HCC resistance. Ther...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Jilkova, Zuzana Macek, Kuyucu, Ayca Zeybek, Kurma, Keerthi, Ahmad Pour, Séyédéh Tayébéh, Roth, Gaël S., Abbadessa, Giovanni, Yu, Yi, Schwartz, Brian, Sturm, Nathalie, Marche, Patrice N., Hainaut, Pierre, Decaens, Thomas
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2018
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834253/
https://ncbi.nlm.nih.gov/pubmed/29541403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24298
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki